- Home
- AVNS vs PHAT Comparison
AVNS vs PHAT Comparison
Compare AVNS & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVNS | PHAT |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 969.8M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AVNS | PHAT |
|---|---|---|
| Price | $24.98 | $10.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 832.3K | ★ 1.2M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.59 | 42.72 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $701,200,000.00 | $175,110,000.00 |
| Revenue This Year | $3.28 | $93.04 |
| Revenue Next Year | $4.23 | $58.91 |
| P/E Ratio | $226.82 | ★ N/A |
| Revenue Growth | 1.95 | ★ 216.93 |
| 52 Week Low | $9.30 | $7.61 |
| 52 Week High | $25.49 | $18.31 |
Technical Indicators
Market Signals| Indicator | AVNS | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 61.68 | 48.04 |
| Support Level | $24.87 | $10.02 |
| Resistance Level | $25.49 | $11.65 |
| Average True Range (ATR) | 0.07 | 0.71 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 100.00 | 34.40 |
Price Performance
Historical ComparisonAbout AVNS Avanos Medical Inc.
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.